Completed

Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Data Collection

Who is being recruted

Chronic Disease+13

+ Hematologic Diseases

+ Hemic and Lymphatic Diseases

Over 18 Years
+17 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
See protocol details

Summary

Principal SponsorPoint Therapeutics
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Completion date provided represents the completion date of the grant per OOPD records

Official TitleStudy of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
NCT00086203
Principal SponsorPoint Therapeutics
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Chronic DiseaseHematologic DiseasesHemic and Lymphatic DiseasesImmune System DiseasesImmunoproliferative DisordersLeukemiaLeukemia, LymphoidLymphatic DiseasesLymphoproliferative DisordersNeoplasmsNeoplasms by Histologic TypePathologic ProcessesPathological Conditions, Signs and SymptomsLeukemia, B-CellLeukemia, Lymphocytic, Chronic, B-CellDisease Attributes

Criteria

6 inclusion criteria required to participate
Men or women ≥18 years of age
Histopathologically confirmed diagnosis of B-CLL expressing surface CD20 of any detectable intensity
Rai Stage III or IV. Rai Stages I and II with massive or progressive lymphadenopathy or hepatosplenomegaly.
Primary resistance to a fludarabine regimen (no PR or CR) or progressive disease within 1 year of a prior response
Show More Criteria
11 exclusion criteria prevent from participating
Therapy for CLL within 4 weeks of Study Day 1 (including chemotherapy, radiation, immunotherapy, cytokine or biologic [with the exception of hematopoietic growth factors]). Patients must have recovered from the adverse effects of prior therapy.
Known primary or secondary malignancy of the central nervous system
Any malignancy within the 5 years immediately prior to the first dose of study medication with the exception of basal cell or non-metastatic squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix
Serum creatinine >2.0mg/dL (>176 micromol/L)
Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 19 locations

Suspended

University of Arkansas for Medical Science

Little Rock, United StatesOpen University of Arkansas for Medical Science in Google Maps
Suspended

Ocala Oncology Center

Ocala, United States
Suspended

Gulfcoast Oncology Associates

St. Petersburg, United States
Suspended

Indiana Oncology/Hematology Consultants

Indianapolis, United States
Completed19 Study Centers